Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections

Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections

Pulmonary infections constitute a substantial health problem worldwide. Here the authors show that phagocytes similar to primitive macrophages can be generated from human induced pluripotent stem cells, by the use of industry-compatible, stirred-tank bioreactors, and applied as a cell-based therapy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mania Ackermann, Henning Kempf, Miriam Hetzel, Christina Hesse, Anna Rafiei Hashtchin, Kerstin Brinkert, Juliane Wilhelmine Schott, Kathrin Haake, Mark Philipp Kühnel, Silke Glage, Constanca Figueiredo, Danny Jonigk, Katherina Sewald, Axel Schambach, Sabine Wronski, Thomas Moritz, Ulrich Martin, Robert Zweigerdt, Antje Munder, Nico Lachmann
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/14b2e8c926bf42f1a34ca9cec6a3b9d0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Pulmonary infections constitute a substantial health problem worldwide. Here the authors show that phagocytes similar to primitive macrophages can be generated from human induced pluripotent stem cells, by the use of industry-compatible, stirred-tank bioreactors, and applied as a cell-based therapy to treat acute bacterial infections in mice.

Ejemplares similares